10,077 reports of this reaction
1.4% of all RITUXIMAB reports
#16 most reported adverse reaction
CONTRAINDICATED PRODUCT ADMINISTERED is the #16 most commonly reported adverse reaction for RITUXIMAB, manufactured by Genentech, Inc.. There are 10,077 FDA adverse event reports linking RITUXIMAB to CONTRAINDICATED PRODUCT ADMINISTERED. This represents approximately 1.4% of all 743,156 adverse event reports for this drug.
RITUXIMAB has an overall safety score of 85 out of 100. Patients taking RITUXIMAB who experience contraindicated product administered should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONTRAINDICATED PRODUCT ADMINISTERED is a less commonly reported adverse event for RITUXIMAB, but still significant enough to appear in the safety profile.
In addition to contraindicated product administered, the following adverse reactions have been reported for RITUXIMAB:
The following drugs have also been linked to contraindicated product administered in FDA adverse event reports:
CONTRAINDICATED PRODUCT ADMINISTERED has been reported as an adverse event in 10,077 FDA reports for RITUXIMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONTRAINDICATED PRODUCT ADMINISTERED accounts for approximately 1.4% of all adverse event reports for RITUXIMAB, making it a notable side effect.
If you experience contraindicated product administered while taking RITUXIMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.